Adero Partners’s Nektar Therapeutics NKTR Stock Holding History

Adero Partners’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$35K	Hold	3,433	–	–	﹤0.01%	258
2024 Q4	$47.9K	Hold	3,433	–	–	﹤0.01%	258
2024 Q3	$67K	Hold	3,433	–	–	﹤0.01%	235
2024 Q2	$63.9K	Hold	3,433	–	–	﹤0.01%	213
2024 Q1	$48.1K	Hold	3,433	–	–	﹤0.01%	202
2023 Q4	$29.1K	Hold	3,433	–	–	﹤0.01%	192
2023 Q3	$30.7K	Hold	3,433	–	–	﹤0.01%	181
2023 Q2	$29.6K	Hold	3,433	–	–	﹤0.01%	165
2023 Q1	$36.2K	Hold	3,433	–	–	﹤0.01%	160
2022 Q4	$116K	Hold	3,433	–	–	0.01%	157
2022 Q3	$184K	Hold	3,433	–	–	0.02%	148
2022 Q2	$182K	Hold	3,433	–	–	0.03%	147
2022 Q1	$278K	Hold	3,433	–	–	0.04%	135
2021 Q4	$696K	Hold	3,433	–	–	0.11%	76
2021 Q3	$925K	Hold	3,433	–	–	0.17%	60
2021 Q2	$884K	Hold	3,433	–	–	0.2%	53
2021 Q1	$1.03M	Hold	3,433	–	–	0.46%	40
2020 Q4	$876K	Buy	+3,433	New	+$887K	0.75%	28

Other funds holding NKTR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Adero Partners's NKTR Position: Q1 2025 in Review

Adero Partners held its Nektar Therapeutics (NKTR) position steady in Q1 2025 at 3,433 shares worth $35K. The position accounts for ﹤0.01% of the portfolio, ranked #258.

Adero Partners first reported a position in NKTR in Q4 2020 and has held it in 18 quarters since. The position peaked at $1.03M in Q1 2021. 154 funds tracked by Wall St. Rank hold NKTR as of Q1 2025.

Adero Partners held 3,433 shares of Nektar Therapeutics worth $35K as of Q1 2025.
Adero Partners left its Nektar Therapeutics share count unchanged in Q1 2025.
Nektar Therapeutics made up ﹤0.01% of Adero Partners's portfolio in Q1 2025, its #258 holding.
Adero Partners first reported a position in Nektar Therapeutics in Q4 2020 and has held it in 18 quarters since.
Adero Partners's Nektar Therapeutics position peaked at $1.03M in Q1 2021.
154 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2025.

Based on Adero Partners's 13F filing for Q1 2025, filed 17 Apr 2025.